

National Cancer Institute
Institutional Review Board
AGENDA (revised 4/25/14)
April 28, 2014
10 CRC/3-1608

- 1. Review of Draft Minutes, April 14, 2014**
- 2. Announcements**
- 3. Old Business**
- 4. New Business**
- 5. Problem Report Forms**
- 6. Other Expedited Actions**
- 7. Continuing Reviews**
- 8. Response to Stips** P131467, "Phase I/II Study of the Treatment of Metastatic Cancer that Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3 HLA-A*01 Restricted TCR-Gene Engineered Lymphocytes and Aldesleukin" - Steve Rosenberg, PI
- 9. Amendment** 10C0052-I, "Phase II Study of Dose-Adjusted EPOCH +/-Rituximab in Adults with Untreated Burkitt Lymphoma, c-MYC+ Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma" - Kieron Dunleavy, PI
- 10. Amendment** 10C0174-J, "Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 Deficiency" - Dennis Hickstein, PI
- 11. Amendment** 13C0009-G, "A Multicenter randomized phase II Study of NPC-1C in Combination with Gemcitabine and nab-Paclitaxel versus Gemcitabine and nab-Paclitaxel alone in Patients with Metastatic or Locally Advanced Pancreatic Cancer Previously Treated with FOLFIRINOX" - Tim Greten, PI
- 12. Amendment** 11C0073-L, "A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation from Related or Matched Unrelated Donors in Pediatric Patients with Hematologic Malignancies" - Nirali Shah, PI
- 13. Amendment** 12C0066-F, "Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors" - Jim Doroshow, PI
- 14. Initial Review** P141525, "Phase I Study of Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas" - Shivaani Kummar, PI
- 15. Initial Review** P141526, "A Phase I Clinical Trial of T-cells Targeting B-cell Maturation Antigen for Previously Treated Multiple Myeloma" - Jim Kochenderfer, PI